LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Alphatec’s Grand Slam Second Quarter
Company News

Alphatec’s Grand Slam Second Quarter

August 7, 2023 2 min read Premium comments

Advertisement

Alphatec’s Grand Slam Second Quarter
Source: Wikimedia Commons and Erik Drost
Secondary#alphatec#patmiles

For the second quarter of 2023, Alphatec Holdings, Inc. (ATEC) dramatically reclaimed the position of #1 market share gainer in the spine industry by reporting a stunning 32% increase in procedure volume with a 7% increase in revenue per case.

Alphatec, under the leadership of Mr. Patrick Miles, was the #1 market share gainer during COVID ravished 2020, then again in 2021 and now, almost certainly, will be the #1 market share gainer for 2023. Globus Medical took the crown away from Alphatec in 2022, but Alphatec has snatched it back.

Here are the numbers:

  • Q2 Sales: $117 million. That’s 39% higher than last year’s second quarter—and well above the forecasts from Wall Street’s analyst corps, who, it’s worth mentioning, are truly enamored with the company.
  • Q2 Surgical Sales Growth: 41% to $102 million.
  • Q2 Gross Profit: 73.2%, up 340 basis points from last year’s 69.5%.
  • Earnings Before Interest, Taxes and Amortization (non-cash) Expenses: $1.5 million up dramatically from the Street’s consensus of a $(1.8) million loss.

But wait, there’s still more. Here’s what one of the top Wall Street analysts, David Saxon CFA with Needham and Company LLC, wrote to institutional investors: “We believe there could still be more upside given conservative procedure volume growth assumptions. We also believe upside on the top-line could allow ATEC to see a faster profitability ramp. Given these points, we reiterate our Buy rating and raise our price target to $20 from $19.”

Wall Street’s analysts are updating their models and consensus for the full year seems to be coalescing around $460 million for the full year and then $545 million for 2024.

What is the secret behind Alphatec’s performance? Three reasons, I think:

  1. Focus on surgeon training – 150 surgeons were trained in the second quarter alone;
  2. An obsession on material improvements in spine surgery – Miles and his team are very good at avoiding distractions. They have one job and one job only. “ATEC’s 100% spine focus gives us a unique ability to create comprehensive, ground-up procedures that directly improve spine care,” said Miles;
  3. Advanced, but integrated, imaging and other digital tools – EOS and navigation-enabled robotics. In short, Alphatec is among a handful of spine companies who are leading surgeons from an artisanal practice to the modern approach of integrating engineered processes.
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2023/08/Alphatec_Chart_WEB.jpg?fit=850%2C417&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2023/08/Alphatec_Chart_WEB.jpg?resize=850%2C417&ssl=1" alt="" width="850" height="417">
Courtesy of RRY Publications LLC ©
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy